Ascendis Pharma wins FDA approval for navepegritide for achondroplasia
Source: SeekingAlpha
2026-02-27 22:31:48 ET
More on Ascendis Pharma
- Ascendis Pharma FY 2025 Results: More Than A Takeover Story
- Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript
- Ascendis: Why I'm Skeptical On Takeover Rumors, Long-Term Targets
- Ascendis Pharma Q4 2025 Earnings Preview
- Ascendis Pharma rises amid takeover speculation
Read the full article on Seeking Alpha
For further details see:
Ascendis Pharma wins FDA approval for navepegritide for achondroplasia
Ascendis Pharma A/S
NASDAQ: ASND
ASND Trading
-0.36% G/L:
$236.195 Last:
205,760 Volume:
$233.87 Open:
ASND Latest News
March 02, 2026 08:43:00 am
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
February 27, 2026 05:57:16 pm
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
ASND Stock Data
$13,394,473,228
60,082,592
N/A
105
N/A
Biotechnology & Life Sciences
Healthcare
DK
Hellerup
